- Home
- LANV vs MDWD Comparison
LANV vs MDWD Comparison
Compare LANV & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- MDWD
- Stock Information
- Founded
- LANV 2015
- MDWD 2000
- Country
- LANV China
- MDWD Israel
- Employees
- LANV N/A
- MDWD N/A
- Industry
- LANV Blank Checks
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- LANV Finance
- MDWD Health Care
- Exchange
- LANV Nasdaq
- MDWD Nasdaq
- Market Cap
- LANV 196.8M
- MDWD 179.1M
- IPO Year
- LANV N/A
- MDWD 2014
- Fundamental
- Price
- LANV $1.66
- MDWD $17.58
- Analyst Decision
- LANV
- MDWD Strong Buy
- Analyst Count
- LANV 0
- MDWD 1
- Target Price
- LANV N/A
- MDWD $28.00
- AVG Volume (30 Days)
- LANV 89.2K
- MDWD 56.2K
- Earning Date
- LANV 08-26-2024
- MDWD 08-14-2024
- Dividend Yield
- LANV N/A
- MDWD N/A
- EPS Growth
- LANV N/A
- MDWD N/A
- EPS
- LANV N/A
- MDWD N/A
- Revenue
- LANV $409,961,427.00
- MDWD $20,141,000.00
- Revenue This Year
- LANV N/A
- MDWD $30.16
- Revenue Next Year
- LANV $76.77
- MDWD $18.44
- P/E Ratio
- LANV N/A
- MDWD N/A
- Revenue Growth
- LANV N/A
- MDWD N/A
- 52 Week Low
- LANV $0.91
- MDWD $7.45
- 52 Week High
- LANV $4.70
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- LANV 47.86
- MDWD 47.81
- Support Level
- LANV $1.60
- MDWD $17.29
- Resistance Level
- LANV $1.82
- MDWD $18.77
- Average True Range (ATR)
- LANV 0.15
- MDWD 0.82
- MACD
- LANV -0.02
- MDWD 0.04
- Stochastic Oscillator
- LANV 21.43
- MDWD 52.88
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.